Alicia Zhang

Capital Markets

• Represented issuers and underwriters in IPOs, registered follow-on equity offerings and at-the-market offering programs, including:
  • BioNTech SE in its $511 million advanced follow-on offering and the related rights offering of American Depositary Shares;
  • the underwriters in multiple public offerings of Repligen Corporation; and
  • the underwriters in the U.S. IPO and global offering of ordinary shares and ADSs of ERYTECH Pharma S.A.
• Represented issuers and underwriters in public and private offerings of senior and subordinated debt, including:
  • Johnson & Johnson and Bristol-Myers Squibb Company in offerings of investment-grade notes; and
  • the underwriters in offerings of investment-grade notes of Jefferies Group and of The Clorox Company.

M&A

• Represented Merck in its:
  • $11.5 billion acquisition of Acceleron Pharma (Nasdaq: XLRN);
  • $1.85 billion acquisition of Pandion Therapeutics (Nasdaq: PAND); and
  • $2.7 billion acquisition of ArQule (Nasdaq: ARQL).
• Represented Astellas in its $3 billion acquisition of Audentes Therapeutics (Nasdaq: BOLD).
• Represented Mavis Discount Tire in its merger with Express Oil Change & Tire Engineers, a Golden Gate Capital portfolio company, to create one of the largest U.S. automotive service platforms.
• Represented Oxford Immunotec (Nasdaq: OXFD) in its $591 million acquisition by PerkinElmer.
• Represented AstraZeneca in:
  
  • the $1.8 billion acquisition of CinCor Pharma (Nasdaq: CINC);
  • the spinoff by MedImmune of discovery stage assets to form biotechnology company, Viela Bio; and
  • the sale of U.S. rights to Synagis and profit participation rights to Sobi for $1.5 billion plus contingent payments.
• Represented Evercore as financial advisor to United Technologies (NYSE: UTX) in its $120 billion merger of equals with Raytheon.
• Represented the special committee to Santander Consumer USA Holdings (NYSE: SC) in a $2.5 billion going private transaction.